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ABSTRACT 
Background: The global prevalence of obesity is on the rise, contributing to an 
increased incidence and prevalence of cardiovascular morbidity and mortality. Obesity 
has adverse effects on cardiac structure and function, directly through a hemodynamic 
overload, and indirectly through cardiovascular risk factors and low-grade 
inflammation. Nevertheless, epidemiologic studies have found that once 
cardiovascular disease has developed, people with obesity may experience better 
prognosis than those with normal weight; a phenomenon termed “the obesity paradox”. 
Aims: The objectives of the present thesis were: 1) to investigate the effect of 
surgically induced long-term weight loss on the incidence of atrial fibrillation and heart 
failure; 2) to study possible mechanisms linking obesity to the development of heart 
failure; and 3) to examine the prognostic significance of different BMI categories on 
outcomes in a cohort of patients with ST-elevation myocardial infarction (STEMI) 
treated with percutaneous coronary intervention (PCI). 
Methods: We analyzed data from the Swedish Obese Subjects (SOS) study, a 
prospective matched intervention study comparing bariatric surgery (n=2,010) and 
conventional obesity treatment (n=2,040). The SOS data was merged with the Swedish 
National Patient Register (NPR) and with the Cause of Death Register (COD). Data 
from the SOS obese control group were used to study the link between obesity and 
heart failure (n=2,040). Data from the Swedish Registry of Catheter-borne Coronary 
Vessel Surgery (SCAAR) (n=25,384) were merged with the COD Register to study 
the prognostic significance of different BMI classes. 
Results:  Surgically induced weight loss resulted in a significantly lower incidence 
of atrial fibrillation and heart failure during long-term follow-up. Atrial fibrillation and 
myocardial infarction, as time-dependent variables, were strongly related to incident 
heart failure. In patients with STEMI treated with PCI, those with BMI > 30 kg/m2 had 
the best outcome in unadjusted analysis, but after adjustment for age and sex 
individuals with BMI 25-30 kg/m2 displayed the best prognosis. Underweight patients 
with BMI < 18.5 kg/m2 had the highest 30-day and 1-year mortality in both unadjusted 
and adjusted analysis. 
Conclusions: In people with severe obesity, bariatric surgery induced a substantial 
and a sustained weight loss which resulted in a lower incidence of atrial fibrillation 
and heart failure. Atrial fibrillation is probably reflected by diastolic dysfunction and 
myocardial infarction is likely to be related to systolic dysfunction, proposing two 
different mechanistic pathways for the development of heart failure. Overweight 
displays the lowest risk for 30-day and 1-year mortality after PCI treatment of STEMI. 
Keywords: obesity, bariatric surgery, atrial fibrillation, heart failure, risk factors, 
myocardial infarction, ST-elevation infarction. 
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Sammanfattning på svenska 
Introduktion: Den globala förekomsten av fetma ökar kontinuerligt, vilket bidrar 
till ökad risk för kardiovaskulär sjuklighet och dödlighet. Fetma har ogynnsam effekt 
på hjärtats struktur och funktion, direkt genom ökad hemodynamisk belastning, och 
indirekt via ökad förekomst av kardiovaskulära riskfaktorer och låggradig 
inflammation. Trots detta så visar epidemiologiska studier att vid etablerad 
kardiovaskulär sjukdom så har patienter med fetma bättre prognos än de som är 
normalviktiga; ett fenomen som har benämnts ” fetma paradoxen”. 
Syfte: Syftet med denna avhandling var 1) att undersöka effekten fetmakirurgi på 
förekomsten av förmaksflimmer och hjärtsvikt; 2) att studera möjliga patofysiologiska 
mekanismer bakom sambandet mellan fetma och hjärtsvikt och 3) att utröna effekten 
av olika BMI-kategorier på prognosen efter behandling av en ST-höjningsinfarkt 
(STEMI) med ballongvidgning och anläggning av stent (PCI). 
Metod: Vi analyserade data från den pågående Swedish Obese Subjects (SOS) 
studien, en prospektivt matchad interventionsstudie som jämför fetmakirurgi (n=2010) 
med konventionell fetmabehandling (n=2040). För att undersöka förekomsten av 
förmaksflimmer och hjärtsvikt slogs data från SOS ihop med det svenska 
patientregistret och det svenska dödsorsaksregistret. För att studera sambandet mellan 
fetma och hjärtsvikt länkades data från SOS kontrollgruppen till samma register. 
Slutligen, för att undersöka den prognostiska betydelsen av olika BMI-kategorier på 
30-dagars och 1-årsöverlevnad efter PCI kopplades data från det svenska 
coronarangiografi- och angioplastikregistret (SCAAR) till det svenska 
dödsorsaksregistret. 
Resultat: Fetmakirurgi resulterade i långvarig viktnedgång samt lägre förekomst av 
förmaksflimmer och hjärtsvikt. Förmaksflimmer och hjärtinfarkt som 
tidsberoendevariabler var starkt relaterade till hjärtsvikt. Patienter med BMI >30 kg/m2 
som behandlades med STEMI hade den bästa överlevnaden i ojusterade analyser, men 
efter justering för ålder och kön hade de med BMI 25–30 kg/m2 det bästa utfallet. 
Magerlagda patienter med BMI <18,5 kg/m2 hade den högsta 30-dagars och 1-
årsdödligheten i både ojusterade och justerade analyser. 
Slutsats: Patienter med fetma som genomgår viktreducerande kirurgi uppvisar 
betydande viktminskning som kvarstår över tid, vilket medför minskad risk för 
utveckling av förmaksflimmer och hjärtsvikt. Förmaksflimmer är sannolikt relaterat 
till ökad stelhet i hjärtat (diastolisk dysfunktion) och hjärtinfarkt är kopplad till sämre 
pumpförmåga (systolisk dysfunktion), vilket indikerar två olika mekanismer som kan 
ge upphov till hjärtsvikt. Övervikt (BMI 25–30 kg/m2) uppvisar den lägsta risken för 
30-dagars och 1-års mortalitet efter PCI behandling av STEMI. 
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ABBREVIATIONS 
Abbreviation Phrase 
AF Atrial fibrillation 
Ang Angiotensin 
BMI Body mass index 
CAD Coronary artery disease 
COD Cause of death 
CRF Cardiorespiratory fitness 
CRP C-reactive protein 
CV Cardiovascular 
CVD Cardiovascular disease 
DSE Diabetes support and education 
DVT Deep vein thrombosis 
FFA Free fatty acids 
FFM Fat free mass 
GB Gastric banding 
GBP Gastric bypass 
GLP‐1 Glucagon like peptide‐1 
HCC Hepatocellular carcinoma 
HDL High density lipoprotein 
HF Heart failure 
HOMA-IR Homeostasis model assessment of insulin resistance 
ICD International Classification of Diseases 
IDF International Diabetes Federation 
IFG Impaired fasting glucose 
IGT Impaired glucose tolerance 
IL Interleukin 
ILI Intensive lifestyle intervention 
IR Insulin resistance 
LDL Low density lipoprotein 
LV Left ventricular 
MetS Metabolic syndrome 
MHO Metabolic healthy obesity 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
NPR National Patient Register 
OA Osteoarthritis 
OSA Obstructive sleep apnea 
PCI Percutaneous coronary intervention 
PE Pulmonary embolism 
PIN Personal identity number 
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R‐RCT Registry‐based randomized prospective clinical trials 
RAAS Renin angiotensin aldosterone system 
RMR Resting metabolic rate 
SCAAR The Swedish Registry of Catheter‐borne Coronary Vessel Surgery 
SOS Swedish obese subjects 
STEMI ST‐elevation myocardial infarction 
T2D Type‐2 diabetes 
TG Triglycerides 
TNF‐α Tumor necrosis factor‐alpha 
UCR Uppsala Clinical Research Center 
VBG Vertical banded gastroplasty 
VO2 Oxygen consumption 
VTE Venous thromboembolism 
WC  Waist circumference 
WHR Waist hip ratio 
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INTRODUCTION 
“THE GLOBAL OBESITY WARNING” 
The incidence of obesity has increased worldwide in an exponential 
manner with a global prevalence estimated to be 13% (1). This has led 
the World Health Organization to declare obesity a global epidemic and 
a worldwide public-health problem (2, 3). Accumulation of body fat is 
the result of a positive energy balance, which is related to a multitude of 
causes. Obesity has an impact on quality of life and is associated with 
frequent occurrence of cardiovascular risk factors (4), co-morbidities (5) 
and increased mortality (6). Globally, obesity-related mortality, has 
become higher than death related to starvation. Considerable and 
sustained weight loss has a beneficial effect on the co-morbidities and 
reduces mortality (7).  
 
HISTORY  
“How the good became ugly then bad” - Garabed Eknoya 
Early in the history of human evolution food was made available 
through hunting and gathering. Collecting food, required a high amount 
of physical activity and a precarious food supply lead to frequent periods 
of food shortages.  These conditions favoured survival in individuals 
with the ability to conserve energy in the form of adipose tissue. As 
such, humans developed control systems that favour energy intake and 
storage, and reduced energy expenditure.  
Later, with the development of agriculture, domestication of animals 
and the technological advances of the eighteenth century, the food 
supply increased gradually. Consequently, reduced physical activity and 
readily accessible food, increased the prevalence of overweight and 
obesity in the society. During this time the cultural perception of 
corpulence was considered aesthetically desirable (8). 
In the early nineteenth century the adverse medical consequences of 
obesity started to become apparent. Today, with increasing sedentary 
behaviour and easily available energy rich food, obesity has reached 
 6 
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epidemic proportions and is one of the leading health threats among the 
world’s population (9). 
EPIDEMIOLOGY 
Since 1975, the worldwide prevalence of obesity has nearly tripled. In 
2016, 39% of adults were found to be overweight, and 13% obese (10). 
Over the past decades, the world has transitioned from a state where the 
majority of the population was underweight to a situation in which 
overweight and obesity have become more common (10). The global 
prevalence of obesity during a forty-year period between 1975 and 2015 
is shown in Figure 1. 
    
   
 
 
 
 
 
 
 
 Figure 1. Global obesity prevalence between 1975 and 2015(11). Published with 
permission from Springer Nature.  
OBESITY IN SWEDEN 
According to the Public Health Agency of Sweden 
(Folkhälsomyndigheten), the prevalence of overweight and obesity has 
been slowly rising and now affects approximately 50% of Swedish 
adults (Figure 2). The prevalence of obesity among adults has been 
estimated to be 15%. 
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Figure 2. Prevalence of overweight in adults in Sweden.     
www.folkhalsomyndigheten.se  
DEFINITION AND ANTHROPOMETRIC 
MEASUREMENTS 
Obesity is defined as excess fat accumulation for a given height, that 
increases the risk for impaired health (12).  
Body mass index (BMI) 
BMI is the most widely used measurement to define and classify obesity. 
It is calculated as weight in kilograms divided by height in meters 
squared and categorized according to World Health Organization 
recommendation (13). It is a measure of weight relative to height and 
not a direct measure of body fat accumulation (Table 1). 
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Table 1. BMI classification according to WHO.  
Classification BMI (kg/m2) 
Underweight <18.5 
Normal weight 18.5–24.9 
Overweight 25.0–29.9 
Obese 
     Class I 30–34.9 
     Class II 35–39.9 
     Class III ≥40 
 
On the one hand, BMI is a convenient and simple index to monitor 
obesity in a population and, therefore, widely used as an estimate of 
body fat accumulation in epidemiological studies. Several reports have 
found a dose-dependent relationship between BMI and adverse health 
outcome such as mortality (14). 
However, BMI, has its limitations as it doesn’t differentiate body fat 
mass from lean body mass. A muscular person with little fat can have a 
high BMI and be categorized as being obese despite a low degree of fat 
mass. For cardiovascular clinical outcomes, a body fat distribution with 
increased visceral adipose tissue has been shown to be an important risk 
factor as compared to subcutaneous fat distribution, which is considered 
to be more neutral with respect to health risks (15, 16). 
Waist Circumference (WC) and Waist Hip Ratio (WHR) 
Waist–hip ratio (i.e. the waist circumference divided by the hip 
circumference) is a measure of body fat distribution. The ratio provides 
an index of both intra‐ abdominal adipose tissue and subcutaneous fat 
(17). Waist circumference represents an estimate of abdominal fat. 
Waist circumference is measured in a standing posture at the midpoint 
between the lower margin of the least palpable rib and the top of the iliac 
crest. Hip circumference is measured around the widest portion of the 
buttocks. Table 2 displays the cut off points of waist and waist/hip ratio 
that have been associated with increased cardiovascular risk in males 
and females, respectively(18). 
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Table 2. WC and WHR cut-off points and risk of metabolic complications. 
 Indicator Cut-off point Risk for complication 
Waist circumference >94 cm (M) >80 cm (W) Increased 
Waist circumference >102 cm (M) >88 cm (W) Substantially increased 
Waist-Hip Ratio ≥0.90 cm (M) 
≥0.85 cm (W) Substantially increased 
                                  M, men; W, women 
Skinfold measurements 
Approximately 40% to 60% of total body fat is located in the 
subcutaneous region. Therefore, measuring the sum of skinfold 
thickness for assessment of body fat is frequently used (19). Most 
equations use the sum of at least three skinfolds to estimate body 
density, from which  an estimate body fat amount can be calculated with 
a reasonable degree of accuracy (20). 
BODY COMPOSITION  
 Body composition is quantified as fat and fat‐free mass (FFM). FFM is 
equal to total body weight minus fat mass and includes the weight of 
organs, skin, bones, body water and muscles (21). 
BODY FAT DISTRIBUTION 
Central fat distribution (android) within the abdominal region, known 
as visceral fat, is related to increased risk for metabolic disturbances, 
leading to cardiovascular disease, and increased all-cause mortality. In 
contrast, fat accumulation in the gluteo-femoral region (pear) is 
associated with reduced prevalence of cardiometabolic diseases as 
compared with patients with a high waist circumference (22, 23) 
(Figure 3).  
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Figure 3. Android (apple) vs Gynoid (pear) body fat distribution.                         
Illustration by Arwa Haamid.  
Epicardial fat may have local effects on the myocardium, including 
cardiomyocyte hypertrophy, myocardial fibrosis, and activation of 
inflammatory pathways relating to macrophage infiltration and cytokine 
gene expression (24). 
In Gothenburg, a research group has shown that a higher ratio of 
abdominal waist over hip circumferences (WHR), as a crude estimate of 
abdominal fat, was predictive of a higher risk of coronary artery disease 
(CAD) whereas no association was shown with BMI as a measure of 
obesity (25). 
MEASUREMENT OF BODY COMPOSITION 
Apart from the anthropometric measurements mentioned above, which 
all have limitations, other methods are available that more accurately 
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determine fat amount and distribution. These include bioelectrical 
impedance analyses and densitometry, imaging methods such as dual 
energy X-ray absorptiometry (DXA), computed tomography scanning 
and magnetic resonance imaging. These methods are either costly and/or 
have a low availability, limiting their use in epidemiological studies 
(11). 
ADIPOSOPATHY 
The adipose tissue organ is a storage depot for excess energy in the form 
of triglycerides. The body fat undergoes a continuous turnover and 
releases free fatty acids (FFA) and glycerol to meet the metabolic needs 
of the body. However, a positive caloric balance in susceptible 
individuals leads to excessive accumulation of adipose tissue 
contributing to metabolic disturbances and in turn to cardiovascular 
disease. 
Deposition of ectopic fat is stored in organs other than adipose tissue 
such as the liver, pancreas, heart, and skeletal muscle and may have a 
local effect on these organs. In certain individuals there is also a shift 
from subcutaneous to visceral fat which is stored in the intraperitoneal 
and retroperitoneal spaces. Visceral fat is more strongly correlated to 
adipokine dysregulation, insulin resistance, and inflammation than fat 
located subcutaneously (16).  
PSYCHOLOGICAL ASPECTS 
People with obesity frequently face a negative attitude, prejudice and 
discrimination due to a belief that obesity is evolved from, a lack of 
willpower, laziness, and/or emotional turmoil (26). In some cases, obese 
people have been confronted with similar preconceived notions when 
consulting the medical profession, resulting in patients feeling 
misinterpreted, humiliated, neglected and rejected(27). This exerts a 
huge psychosocial burden on obese people, who struggle with issues 
related to mood, self-esteem, quality of life, and body image. It has been 
estimated that 20-60% of individuals with obesity suffer from a 
psychiatric illness such as depression, anxiety, eating disorders and 
substance abuse (28). 
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APPETITE REGULATION 
The hypothalamus is the center for regulation of food intake and energy 
metabolism (Figure 4). Signals increasing appetite are mainly mediated 
by neuropeptide Y (NPY) and agouti-related regulatory peptide (AgRP). 
Signals inducing satiety are mostly facilitated by pro-opiomelanocortin 
(POMC) (29). The digestive tract communicates with the hypothalamus 
via the vagus nerve which is stimulated by mechanoreceptors 
responding to gastric distension, to chemical signals and to a variety of 
local neurohormones (30). Examples of local gut peptides affecting 
appetite include, gherelin, which enhances appetite and cholecystokinin 
(CCK), peptide YY (PYY) and glucagon like peptide-1 (GLP-1), which 
all suppress appetite. Adipocytes produce leptin which crosses the blood 
brain barrier and suppresses the appetite by activating POMC neurons 
and inhibiting NPY and AgRP neurons in the hypothalamus. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. A simplified schematic illustration of appetite regulating mechanisms.                                        
Adapted and simplified from Ueno et al., JDI 2016. 
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ASYMMETRICAL REGULATION OF ENERGY 
BALANCE 
The regulation of energy balance has been found to be   asymmetrical. 
(Figure 5). The responses that counteract body fat accumulation during 
times of overfeeding are rather weak regulatory responses aimed at 
restoring energy balance, whereas the signals that arise during energy 
deficit and resist weight loss are considerably more potent (31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A schematic illustration showing regulation of energy balance. Adapted 
from Hopkins and Bundel 2016.  *Free fat Mass **Resting metabolic rate 
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OBESITY AND CARDIOVASCULAR RISK FACTORS  
Chronic accumulation of excess body fat induces metabolic changes, 
leading to the development of CV risk factors and activation of low 
grade inflammation (32). Obesity, and central obesity in particular, is 
associated with hypertension, dyslipidemia, glucose intolerance, 
increased levels of inflammation, obstructive sleep apnea, and a 
prothrombotic state. Obesity is also associated with a progressive 
decline in physical activity and cardiorespiratory fitness, and has itself 
been shown to be and independent risk factor for CV diseases (33-35). 
Obesity is associated with hemodynamic changes that affect left 
ventricular structure and function (36). Augmented fat mass is linked to 
increased total blood volume, decreased systemic vascular resistance, 
and a rise in left ventricular (LV) stroke volume, cardiac output and LV 
filling pressures. This in turn stimulates LV hypertrophy, left atrial 
enlargement, and impaired LV systolic and diastolic function. Body fat 
accumulation is also related to higher pulmonary pressure, greater right 
ventricular end-diastolic volume and mass (35). The mechanisms by 
which obesity may cause cardiac dysfunction are displayed in Figure 6. 
 
 
 
 
 
 
 
 
 
 
Figure 6. Visceral obesity and cardiovascular risk, a multifactorial and complex 
mechanism. Adapted from Majorie Bastien et al, 2014 and Lavie et al. 2013. 
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Hypertension 
Individuals with central obesity have a 3-fold higher likelihood of 
having hypertension as compared to those with normal body weight 
(37). Among individuals with a BMI >30 kg/m2 the prevalence of 
hypertension was over 40% (38). Increased renal tubular sodium 
reabsorption, mediated through activation of the renin-angiotensin-
aldosterone system (RAAS) (39) and increased sympathetic nervous 
system (SNS) activity (40), have been suggested to play an important 
role in linking obesity with hypertension.  
Angiotensinogen (AGN) is produced in the liver and by adipocytes. It is 
then transformed to angiotensin (Ang) I by renin, secreted by the 
kidneys. Angiotensin converting enzyme (ACE) transforms Ang I to 
Angiotensin II which is a powerful vasoconstrictor and promotes cardiac 
myocyte hypertrophy and cardiac interstitial fibrosis (32). It has also 
been shown that Ang II, interferes with preadipocyte differentiation to 
adipocytes, and thereby contributes to the formation of large and 
dysfunctional adipocytes (41). The expression of AGN is increased in 
large adipocytes, which leads to activation of RAAS, a mechanism 
involved in obesity-associated hypertension (32). 
Dyslipidemia 
Dyslipidemia in obesity consists of increased triglycerides (TG) and 
fatty free acids (FFA), decreased high density lipoprotein (HDL) with 
HDL dysfunction and normal or slightly increased low-density 
lipoproteins (LDL) with increased small dense LDL (VLDL). The 
concentrations of plasma apolipoprotein (apo) B are also often 
increased, partly due to the hepatic overproduction of apo B containing 
lipoproteins (42). HDL-cholesterol has demonstrated protective 
properties against atherothrombosis. In contrast, low levels of plasma 
HDL-cholesterol are associated with CAD and are a better predictor of 
ischemic heart disease than LDL-cholesterol levels (43). From a clinical 
standpoint,  low levels of HDL-cholesterol are rarely an isolated finding, 
and frequently associated with high triglycerides (TG), high Apo B, and 
increased insulin resistance (32). 
Weight loss by increased exercise and improved dietary habits lead to 
improvement in the lipid status. Medical therapy can be initiated if 
lifestyle changes are insufficient. Statins, reduce LDL and remnant 
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cholesterol levels. Combination of statins and fibrates are used TG 
levels are high and HDL-cholesterol levels are low (44). 
Insulin resistance and T2D 
Normal regulation of glucose metabolism is determined by the islet β-
cell response and tissue sensitivity to insulin. When insulin resistance is 
present, the β-cell maintains normal glucose tolerance by increasing 
insulin output. In the presence of obesity-related insulin resistance, the 
β-cell becomes incapable of releasing sufficient insulin leading to 
increased glucose levels, prediabetes and T2D (45). Abdominal obesity 
is associated with prediabetes, defined as IFG > 6.1 mmol/L and/or 
impaired glucose tolerance (IGT) [7.8 mmol/L-11.0 mmol/L]. 
Prediabetes is a risk factor for diabetes and cardiovascular disease (46). 
The earliest detectable metabolic defect in patients with obesity is 
augmented insulin resistance (IR) (47). The adipocytes in central obesity 
are dysfunctional and increase the rate of lipolysis leading to elevated 
plasma FFA concentrations (48) which inhibit insulin stimulated 
peripheral glucose uptake. This causes peripheral and hepatic insulin 
resistance. The consequences are  overproduction of hepatic glucose and 
underutilization of peripheral sugar giving rise to T2D (49).  
It has also been shown that central obesity is associated with an 
increased prevalence of T2D. For a given BMI value, the WC in patients 
with diabetes was higher (50). In another study, the risk of developing 
T2D increased by 20% for each increase in a BMI unit (51). 
Approximately 50% of patients with T2D have obesity (52). 
The higher the BMI, the greater the IR (53). IR develops due to higher 
FFAs levels and elevated inflammatory markers. CRP and TNF-α 
mediate the development of T2D in individuals with obesity (54, 55). IR 
and a deficit in insulin secretion due to decreased pancreatic β-cell 
function are mechanisms underlying the development of T2D in obese 
people (56).   
Metabolic Syndrome 
Metabolic syndrome (MetS) is a constellation of cardiovascular disease 
risk factors comprising central obesity, systemic hypertension, IR and 
atherogenic dyslipidemia (specifically hypertriglyceridemia and 
reduced levels of high-density lipoprotein cholesterol). The syndrome 
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has been defined by various organizations that have used different 
criteria. One of the most widely used definitions from the International 
Diabetes Federation (IDF) 2005 is displayed in Table 3. Increased 
sedentary lifestyle is a major factor for increased prevalence of MetS 
which can be prevented by physical exercise and dietary treatment.  
Table 3. IDF classification of MetS. 
Waist > 94 cm for men or > 80 cm for women along with 
the presence of two or more of the following: 
Blood glucose > 5.6 mmol/L or diagnosed diabetes 
HDL cholesterol < 1.0 mmol/L in men, < 1.3 mmol/L in women or drug treatment for low HDL-C 
Blood 
triglycerides 
> 1.7 mmol/L or drug treatment for elevated 
triglycerides 
Blood pressure > 130/85 mmHg or drug treatment for hypertension 
 
Inflammation 
Central obesity is associated with increased circulating levels of 
interleukin (IL)-6, tumor necrosis factor-α (TNF-α), and C-reactive 
protein (CRP) (57, 58).?It has also been shown that the severity of the 
metabolic syndrome, is positively related to CRP levels (59). Leptin, an 
adipokine produced by adipose tissue, has been shown to be an 
independent predictor of CVD (60). Another adipokine with anti-
inflammatory activity, adinopectin, was shown to be positively related 
to the risk of cardiovascular events in patients with established CAD 
(61).  
Prothrombotic state 
Obesity is associated with an increased risk for venous 
thromboembolism (VTE) (62) which encompasses two distinct clinical 
entities: deep vein thrombosis (DVT) and pulmonary embolism (PE). A 
meta-analysis has shown that the likelihood of a first spontaneous VTE 
among people who are obese was more than twice that of individuals 
with a normal BMI (63). The relative risk of unprovoked PE is raised by 
8% per 1 kg/m2 increase in BMI and approaches a nearly six fold greater 
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risk among individuals with a BMI ≥ 35 kg/m2 (64). Intentional weight 
loss and physical activity reduce the risk for VTE among people with 
obesity (65). 
Hemodynamic overload 
Increase in body weight leads to a higher metabolic demand which 
results in increased blood volume and cardiac output (66-68). A higher 
BMI is directly related to an increase in renal tubular sodium 
reabsorption which leads to sodium retention and subsequent plasma 
volume expansion (69, 70). Thus, obesity contributes to a higher cardiac 
output, increasing the preload and augmenting the cardiac workload 
leading to greater LV mass (71). Volume overload leads to eccentric 
cardiac hypertrophy with enlarged chambers and normal wall thickness 
(72).  
Under these conditions cardiac afterload is also elevated.  This is 
because systemic peripheral resistance does not decline to the same 
degree as the rise that occurs in cardiac output  (73).  A higher BMI is 
associated with increased blood pressure (37) and pressure overload 
results in a concentric hypertrophy a phenotype characterized by thick 
ventricular walls and normal LV volume (74-76). As a consequence, 
obese people may display a combination of eccentric and concentric LV 
hypertrophy (77). 
Abdominal adiposity shows a stronger relationship with concentric LV 
remodeling, including greater left ventricular mass, but also increased 
left ventricular end diastolic volume. The degree of abdominal adiposity 
is positively correlated with the ejection fraction whereas, the duration 
of overall obesity was inversely associated with a lower ejection fraction 
(78). 
 OBESITY AND CARDIOVASCULAR DISEASE (CVD) 
Atrial fibrillation (AF) 
Obesity is a risk factor for AF. It has been shown that for each increase 
in one unit of BMI, the risk for AF rises by 4%. Further, obesity 
independently predicts a transition from paroxysmal to permanent AF 
and is also associated with a higher recurrence rate and greater burden 
of AF (79-81). Obesity contributes to the development of AF through 
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comorbidities like hypertension, coronary artery disease, diabetes 
mellitus, obstructive sleep apnea, and congestive heart failure (82, 83). 
It is plausible that significant weight reduction would reduce the risk of 
new-onset AF, but there is little evidence to support such a belief. 
Heart failure (HF) 
Obesity is associated with a two-fold higher risk of developing heart 
failure compared to normal weight (82). The risk of heart failure 
increases by 5–7% for each increment of BMI (82). Furthermore, one 
unit increase in BMI, has been shown to be associated with a higher risk 
for future HF with preserved ejection fraction (HFpEF) compared to HF 
with a reduced ejection fraction (HFrEF) (84). In men, a higher BMI 
was independently associated with both HF subtypes where as in 
women, BMI was associated with incident HFpEF but not HFrEF (84). 
In the normal population, HF is represented by about one half HFpEF 
and one half HFrEF (85). Patients with HFpEF are generally more 
obese, older and have a higher prevalence of hypertension, diabetes, and 
atrial fibrillation than those with HFrEF. Coronary artery disease and 
coronary risk factors are clinical comorbidities in both, HFpEF and 
HFrEF (86, 87).  
Although obesity intervention can improve cardiovascular risk factors 
and may have beneficial effects in patients with compromised cardiac 
function there are no large controlled studies investigating the impact of 
weight loss on the development of heart failure. 
Coronary artery disease (CAD) 
Obesity is an independent risk factor for CAD (88), and over 80% of 
patients with CAD are overweight or obese. After diagnosis, obesity is 
associated with accelerated progression of CAD (89, 90). Weight 
control is considered to be of fundamental importance in primary 
prevention aimed at reducing the overall incidence of cardiovascular 
disease (91) and is also targeted in secondary preventive programs 
intended to improve outcome in patients with established cardiovascular 
disease (92, 93). Still, a certain hesitancy has arisen concerning the 
beneficial effects of weight loss as a secondary prevention practice, 
since several epidemiologic studies have suggested that obesity may be 
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protective in patients with coronary artery disease undergoing 
intervention (94, 95). 
OBESITY AND OTHER CO-MORBIDITIES 
Increase in total body fat, specifically abdominal fat, is associated with 
an increase in health risk. The amount of body fat has been associated 
with an increased risk of comorbidities like joint pains and osteoarthritis, 
obstructive sleep apnea, non-alcoholic fatty liver disease and some types 
of cancer. 
Joint pains and osteoarthritis (OA) 
People with obesity have a high prevalence of joint pain, especially in 
the lumbar spine and knees, as well as OA in the hips and knees (96, 
97). Obesity, apart from causing mechanical overload, causes release of 
inflammatory cytokines including leptin and resistin which influence the 
onset and worsening of OA through direct degradation of the joint or 
stimulation of inflammatory processes (97). Weight loss through 
bariatric surgery has been shown to improve OA symptoms (98). 
Obstructive sleep apnea (OSA) 
OSA is a condition characterized by repeated episodes of partial or 
complete obstruction of the respiratory passages during sleep. People with 
central obesity have a high prevalence of OSA. Accumulation of fat in the 
upper body, especially around the neck, in the respiratory area and in the 
diaphragm, gives rise to OSA (99, 100). A reciprocal relationship exists 
between the development of OSA and its subsequent sleep fragmentation 
which appears to accelerate weight gain. Many patients report rapid 
increases in weight in the year prior to OSA diagnosis (101). There is 
evidence linking OSA as an independent risk factor for hypertension (102), 
atrial fibrillation, ischemic heart disease,  stroke and mortality (103).  
Non-alcoholic fatty liver disease (NAFLD) 
The increase in the worldwide prevalence of obesity has led to an 
increase prevalence of NAFLD which is estimated to affect around 25% 
of the general population. In the western world, approximately 83% of 
patients with central obesity have NAFLD which is one of the leading 
causes of chronic liver disease. NAFLD is divided into a non-
progressive form of simple liver steatosis and a progressive form of non-
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alcoholic steatohepatitis (NASH) that can lead to cirrhosis, 
hepatocellular carcinoma (HCC) and liver-related mortality (104, 105).  
Cancer 
It has been shown that an increase in BMI by 5 kg/m² in men is strongly 
associated with esophageal adenocarcinoma, thyroid carcinoma, colon 
cancer, and renal cancers. In women, a similar increase in BMI is 
associated with endometrial, gallbladder, renal cancer and esophageal 
adenocarcinoma (106).  
METABOLIC HEALTHY OBESE (MHO) 
MHO is a phenotype of obesity where individuals lack features of the 
metabolic syndrome. Several definitions exist for MHO, but in studies 
the most widely used classification requires the individual to have ≥2 of 
the following five metabolic syndrome components: high systolic and 
diastolic blood pressures, high plasma TG concentration, low HDL-C 
concentration, high fasting blood glucose, and a large waist 
circumference (107); or having ≥1 abnormal component excluding waist 
circumference (108). Additional criteria include indices of insulin 
sensitivity/resistance based on the homeostasis model assessment of 
insulin resistance (HOMA-IR) score(109). When metabolically healthy, 
definition is the absence of MetS, about 50% of people with obesity fall 
into this category. When the definition includes absence of MetS and a 
normal HOMA-IR, only 5% are considered metabolically healthy (110). 
Studies have shown MHO is often a temporary state and frequently 
transforms into a metabolically unhealthy condition with an elevated 
long-term risk of developing CVD (111, 112). In general, the risks of 
T2D, CVD, and all-cause mortality are higher in people with obesity 
who have the metabolic syndrome than in those with MHO (112). 
However, further research is required to understand the mechanisms 
responsible for preserved metabolic health in obese people and to enable 
a consensus concerning the definition of MHO.  
WEIGHT LOSS STRATEGIES 
There are mainly three different types of weight loss interventions 
namely, life style intervention, pharmacotherapy and bariatric surgery. 
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Lifestyle intervention 
Lifestyle intervention includes, caloric restrictions using specific diets 
e.g. very low energy diets where the daily energy intake is restricted to 
450-800 kcal (1855-3297 kJ). Increase in physical activity 
(approximately 1 h per day) is another lifestyle intervention aimed to 
facilitate weight loss (113). Exercise may not reduce body weight as 
such, but instead alters body composition by increasing lean body mass 
and reducing visceral fat; ‘waist loss rather than weight loss’. Such 
changes in body composition appear to be advantageous with respect to 
cardiovascular risk (16) Behavioural changes like self-monitoring and 
goal setting can also be encouraged.  
The results of intensive lifestyle intervention (ILI), however, rarely 
result in weight loss to a degree that is sufficient to reduce 
cardiovascular events. In the Look-AHEAD trial, patients with obesity 
and T2D were randomized to either an ILI or diabetes support and 
education (DSE). The ILI group received treatment consisting of diet 
modification and increased physical activity to achieve a sustained 
weight loss (114). The DSE control group were, apart from regularly 
scheduled clinic visits, offered yearly educational sessions covering 
diet/nutrition, exercise and social support.  After a median follow-up of 
9.6 years, the mean weight loss for the ILI group was −6.0 %   and for 
the DSE group −3.5 %. Still, there was no overall significant difference 
in the primary composite CVD outcome between the groups. Weight 
loss achieved through lifestyle intervention is difficult to maintain over 
time and, therefore adjuvant therapies should be considered (115).  
Pharmacotherapy 
In Sweden, pharmacotherapy is recommended in patients with obesity 
(BMI ≥ 30 kg/m2) and in overweight patients (BMI ≥ 27 kg/m2) who 
have risk factors for cardiovascular disease. 
• Orlistat  
 
Orlistat blocks the enzyme lipase which is found in the 
intestine and breaks down fats. As a result, about 30% of 
the total fat intake passes out undigested in the faeces. 
Orlistat does not inhibit the metabolism of sugars and 
other non-fat foods. Therefore, calorie intake from these 
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and other food sources still need to be restricted in 
patients. 
 
• Liraglutide and semaglutide 
 
Liraglutide and semglutide are glucagon like peptide‐1 
(GLP‐1)  receptor agonists that induce weight loss by 
appetite suppression and delayed gastric emptying (116, 
117). 
 
• Naltrexone/bupropion 
 
Naltrexone/bupropion is a combination drug, which 
induces weight reduction through an effect on the brain’s 
appetite regulation. Naltrexone is an opiate antagonist 
targeting pathways in the central nervous system that 
impact eating behavior, presumably influencing the food 
reward system. Bupropion, is an antidepressant that 
inhibits reuptake of noradrenaline and dopamine and is 
also thought to affect the brains appetite regulation 
through a different mechanism. When combined with 
lifestyle interventions these agents can induce a 
clinically significant weight loss for up to one year 
(118).  
 
• SGLT2 inhibitors 
 
Sodium-glucose cotransporter-2 inhibitors are currently 
approved for treatment of T2D. These inhibitors reduce 
renal tubular reabsorption of sodium and glucose, 
resulting in increased urinary secretion of sodium and 
glucose. In addition to lowering blood glucose, these 
agents induce weight loss, lower blood pressure, reduce 
the incidence of heart failure, and improve CV outcomes 
(119). 
Bariatric Surgery 
For people with obesity, bariatric surgery is a therapeutic option that 
results in substantial weight loss that is maintained over time (7, 120-
123). Sustained weight loss leads to improvement in cardiovascular risk 
factors including hypertension, dyslipidemia and type 2 diabetes 
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mellitus. Furthermore, obesity surgery reduces cardiovascular events, 
lowers cancer incidence and contributes to better survival (7, 120, 123-
127). According to the Scandinavian Obesity Surgery Registry, about 
5,200 bariatric surgical procedures using a laparoscopic technique were 
performed in Sweden during 2018. Gastric bypass was the most 
common procedure closely followed by sleeve gastrectomy (128). 
Figure 4 shows the two most common surgical methods, gastric bypass 
and sleeve gastrectomy, that are applied today. 
a)                                                                 b)                                                                
  
 
 
 
 
 
 
 
 
Figure 7. a) Gastric bypass and b) sleeve gastrectomy. Illustration by Arwa Haamid. 
SIDE EFFECTS OF BARIATRIC SURGERY 
Dumping syndrome, is a common complication after bariatric surgery. 
Typically, symptoms arise after a meal and include abdominal pain, 
nausea, diarrhea, and also vasomotor symptoms such as fatigue, 
flushing, palpitations, perspiration, tachycardia and hypotension (129). 
Nutritional deficiencies are the most common long-term complications 
of bariatric surgery resulting from inadequate food intake, 
malabsorption, or both. Anemia, caused by deficiencies of iron and 
vitamin B12, is common. Other deficiencies include folate, selenium, 
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zinc, copper, and vitamins A, B1, B2, B6, C, D, E and K. Therefore, 
lifelong follow-up is recommended with provision of supplements to 
ensure an optimal nutritional status (130-132). After bariatric surgery, 
an increased alcohol consumption has been reported, and other alcohol-
related problems, such as alcohol abuse (133) and increased risk for new 
onset of depression and suicide (134). 
THE OBESITY PARADOX 
Obesity is associated with an increased prevalence of hypertension, AF, 
HF and CAD (82, 89, 135, 136). On the other hand, epidemiological 
studies show that once CVD is present, obese patients have a better 
prognosis than their leaner counterparts, which is referred to as the 
obesity paradox (137-139) (Figure 8). The obesity paradox may be 
derived from an interaction between several potential confounders.  
Such confounders can be related to an elevated BMI due to high lean 
body mass or subcutaneous fat distribution. A low BMI could be due to 
chronic illness leading to cachexia. Another confounding source is not 
being able to account for high levels of CRF despite obesity. Thus, the 
protective effect of excess body fat is somewhat counter intuitive and a 
mechanism involving reverse causality has been suggested (140). 
.   
 
 
 
 
 
                             
 
                         
Figure 8 The obesity paradox. Illustration by Arwa Haamid. 
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Fat distribution, fat mass and lean mass 
The use of BMI as a measure of adiposity in epidemiological studies has 
shortcomings since it does not discriminate between body fat and lean 
mass, nor does it reflect body fat distribution. It has been shown that 
WC or WHR as estimates of abdominal obesity, correlate more strongly 
to CVD than BMI, and are better markers of abdominal obesity than 
BMI (23, 141).  In patients with CAD, a higher lean mass was associated 
with lower mortality rather than body fat (142). BMI values seen in 
overweight and mildly obese patients can be due to increased lean mass 
and not to elevations in body fat. Increased lean mass has been shown 
to be associated with better fitness and exercise capacity, improvement 
in metabolic profiles and probably better prognosis in patients with 
cardiovascular diseases (143-145). 
Intentional versus unintentional weight loss 
Intentional weight loss through diet and physical exercise, results in loss 
of body fat and an increase in lean body mass. A higher lean mass is 
associated with better survival (146). Unintentional weight loss where 
there is loss of both body fat and lean mass is associated with a higher 
mortality (147). Cachexia is often related to an  underlying chronic 
disease which leads to frailty and adverse outcomes (148). Also, a lower 
BMI has been related to low lean mass, a condition also known 
as sarcopenia (149). Patients with sarcopenia have decreased muscle 
mass, a restricted exercise capacity and reduced mobility, both 
conditions associated with increased total mortality (150). 
 
Cardiorespiratory fitness (CRF) 
Physical activity (PA) and improvements in CRF are associated with 
lower CVD mortality, independent of weight or BMI (151). Lower 
mortality was observed in patients with HFrEF that displayed a peak 
oxygen consumption (VO2) >14 mL/kg/min, indicating a higher level of 
CRF. In contrast, in patients with peakVO2 < 14 mL/kg/min, suggesting 
poor CRF, had a higher mortality (152, 153). 
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SWEDISH PERSONAL IDENTITY NUMBER AND 
NATIONAL HEALTH REGISTERS  
In Sweden, every child that is born, and all immigrants who receive 
Swedish citizenship are assigned a unique personal identity number 
(PIN) by the National Tax Board. The PIN is updated in the total 
population register database by Statistics Sweden. In medical research, 
the PIN is used to  link patient data to various national registers like, the 
Swedish National Patient Register (NPR), the Swedish Cancer Register 
and the Swedish Cause of Death Register (COD) (154).  
A number of national registers are administered by The National Board 
of Health and Welfare (Socialstyrelsen), including, NPR, COD, as well 
as the Swedish Cancer Register and the Swedish Medical Birth Register.  
 The Swedish National Patient Register (NPR)  
From 1987 NPR includes diagnoses for all in-patient care, and since 
2001 it covers diagnoses for both in- and outpatient doctor visits 
including day surgery and psychiatric care from both private and public 
caregivers. Primary care, however, is not covered. Diagnoses at 
discharge are coded with the International Classification of Diseases 
(ICD). Reporting to the register is exceptionally high. The register has 
been validated by quality controls performed on the submitted data 
(155). Primary diagnoses of atrial fibrillation and heart failure have 
shown to have a high validity (156, 157).  
The Swedish Cause of Death Register (COD) 
The Swedish National Board of Health and Welfare has administered 
the COD since 1994. ICD codes system and the World health 
organization (WHO) standardized systems for certifying deaths are 
used. Since 1997 all deaths reported to the tax authority have been 
included in the register, which covers almost all underlying causes of 
death in the Swedish population. It has been shown that there is a 77% 
agreement between the cause of death from death certificates and the 
cause of death based on medical records (158). 
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SWEDISH PERSONAL IDENTITY NUMBER AND 
NATIONAL HEALTH REGISTERS  
In Sweden, every child that is born, and all immigrants who receive 
Swedish citizenship are assigned a unique personal identity number 
(PIN) by the National Tax Board. The PIN is updated in the total 
population register database by Statistics Sweden. In medical research, 
the PIN is used to  link patient data to various national registers like, the 
Swedish National Patient Register (NPR), the Swedish Cancer Register 
and the Swedish Cause of Death Register (COD) (154).  
A number of national registers are administered by The National Board 
of Health and Welfare (Socialstyrelsen), including, NPR, COD, as well 
as the Swedish Cancer Register and the Swedish Medical Birth Register.  
 The Swedish National Patient Register (NPR)  
From 1987 NPR includes diagnoses for all in-patient care, and since 
2001 it covers diagnoses for both in- and outpatient doctor visits 
including day surgery and psychiatric care from both private and public 
caregivers. Primary care, however, is not covered. Diagnoses at 
discharge are coded with the International Classification of Diseases 
(ICD). Reporting to the register is exceptionally high. The register has 
been validated by quality controls performed on the submitted data 
(155). Primary diagnoses of atrial fibrillation and heart failure have 
shown to have a high validity (156, 157).  
The Swedish Cause of Death Register (COD) 
The Swedish National Board of Health and Welfare has administered 
the COD since 1994. ICD codes system and the World health 
organization (WHO) standardized systems for certifying deaths are 
used. Since 1997 all deaths reported to the tax authority have been 
included in the register, which covers almost all underlying causes of 
death in the Swedish population. It has been shown that there is a 77% 
agreement between the cause of death from death certificates and the 
cause of death based on medical records (158). 
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THE SWEDEHEART REGISTRY 
The Swedish Web-system for Enhancement and Development of 
Evidence-based care in Heart disease Evaluated According to 
Recommended Therapies (SwedeHeart) is a national registry that was 
established in 2009. The SwedeHeart registry is administered by 
Uppsala Clinical Research Center (UCR) and is sponsored solely by the 
Swedish Health Authorities, in particular, the Swedish Association of 
Local Authorities and Regions (159). Several registry-based 
randomized prospective clinical trials (R-RCT) have been performed, 
with TASTE (160), being one of the first R-RCT. Others include, iFR-
SWEDEHEART (161), DETO2X-AMI (162) and VALIDATE-
SWEDEHEART (163).  
Presently, the database includes the following national registries: 
 
• The Registry of Acute Infarction Care (RIKS-HIA). 
• The Registry of Secondary Preventive Care after 
Cardiac Infarction (SEPHIA). 
• The Registry of Catheter-borne Coronary Vessel 
Surgery (SCAAR). 
• The Registry of Catheter-borne Valve Replacement 
(TAVI). 
• The Registry of Open-Heart Surgery (Svenska 
Hjärtkirurgiregistret). 
All patients admitted to hospital for acute coronary syndrome 
investigations, those being followed up in out-patient clinics for 
secondary prevention, and individuals undergoing coronary- or valvular 
intervention are included in this registry. The registry database is 
directly connected to the Swedish National Population Registry and 
merged, on a yearly basis, with the NPR, COD registry, and the National 
Registry of Drug Prescriptions.  
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AIMS 
The main underlying hypothesis of the present thesis was that weight 
loss through bariatric surgery is advantageous for cardiovascular risk. 
Also, that obesity may exert a protective effect with respect to outcomes 
after a coronary artery event. In order to address these hypotheses, we 
formed the following research proposals: 
Paper Ⅰ?
To investigate whether weight loss through bariatric surgery may reduce 
the risk of new-onset atrial fibrillation among people with obesity. 
Paper Ⅱ 
To examine the effect of surgical obesity treatment on the incidence of 
new-onset heart failure. 
Paper Ⅲ 
To determine risk factors for the development of heart failure in 
obesity including both variables registered at baseline as explanatory 
variables as well as atrial fibrillation and myocardial infarction as 
time-dependent variables. 
 
Paper Ⅳ?
To explore the obesity paradox in a ST-elevation myocardial infarction 
cohort who had undergone percutaneous coronary intervention. 
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PATIENTS AND METHODS 
PaperⅠ? Paper Ⅱ????Paper Ⅲ 
In Paper I and Paper II, patients were included from the ongoing, 
nonrandomized, matched, prospective, controlled Swedish Obese 
Subjects (SOS) intervention study. A total of 4047 eligible obese 
participants were enrolled between September 1, 1987, and January 31, 
2001. The inclusion criteria were age between 37 to 60 years and BMI 
of at least 34 for men and at least 38 for women. 
Subjects were excluded if they had a history of earlier surgery for gastric 
or duodenal ulcer, earlier bariatric surgery, gastric ulcer during the past 
6months, ongoing malignancy, active malignancy during the past 5 
years, myocardial infarction during the past 6months, bulimic eating 
pattern, drug or alcohol abuse, psychiatric or cooperative problems 
contraindicating bariatric surgery, or other contraindicating conditions 
(such as chronic glucocorticoid or anti-inflammatory treatment). The 
study complied with the Declaration of Helsinki and seven regional 
ethics review boards in Sweden approved the study protocol. All 
participants gave written or oral consent. 
Individuals who expressed a preference for treatment with bariatric 
surgery constituted the surgery group consisting of 2010 participants. 
The bariatric surgical procedures in the study at that time included 
vertical banded gastroplasty (VBG) (68%) gastric banding (GB) (19%), 
and gastric bypass (GBP)(13%) shown in Figure 9. 
A matched control group, of 2040 participants, was created using an 
automatic computerized matching program with 18 matching variables. 
The matching variables included sex, age, weight, height, waist-hip 
ratio, blood pressure, serum cholesterol, triglycerides, smoking, 
diabetes, menopause, 4 psychosocial variables associated with risk for 
death, and 2 personality traits related to treatment preferences. Among 
the 2040 patients in the control group, there were three patients who 
were initially scheduled for surgery, but changed their mind and had 
declined surgical intervention. The conventional treatment offered to 
control subjects was according to routine local practice of the health care 
centers. 
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Figure 9. Surgical techniques used in the SOS study. A) Vertical-Banded Gastroplasty  
B) Gastric Banding C) Gastric Bypass 
At each visit, measurements of weight, height, waist circumference, and 
blood pressure were obtained. The SOS database was merged with the 
NPR to obtain data on new-onset AF. Further, incident HF diagnosis 
was achieved by merging SOS with the NPR and COD registries. The 
two study groups underwent identical examinations at the participating 
surgical departments and primary health care centers both at baseline 
and during follow-up at 0.5, 1, 2, 3, 4, 6, 8, 10, 15, and 20 years. 
After bariatric surgery, the recommended daily nutritional 
supplementation included oral doses of multivitamin and mineral 
supplements, vitamin B12, and a combination of calcium and vitamin 
D3. If laboratory findings indicated deficiencies of iron or folate, 
replacement therapy was introduced. Matched control patients received 
standard nonsurgical obesity treatment from their primary health care 
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centers. No attempt was made to standardize the conventional treatment 
which ranged from sophisticated lifestyle intervention and behavior 
modification to, in some practices, no treatment at all. 
Body weight was measured with electronic or calibrated scales at 
baseline and at regular follow-up appointments. Blood samples were 
analyzed by the Central Laboratory at Sahlgrenska University Hospital 
(accredited according to the international standard ISO 15189:2012). 
Self-reported information on cardiovascular disease, medication, 
smoking, and alcohol intake was obtained through a questionnaire 
administered. High blood pressure was defined as systolic pressure 
>140mmHg, or diastolic pressure > 90mmHg, or self-reported use of 
anti-hypertensive medication. Diabetes was defined as a fasting blood 
glucose level of at least 6.1mmol/L (110mg/dL) or self-reported use of 
a prescribed antidiabetic medication.at baseline and during follow-up 
visits. In Paper I, all patients that had reported atrial fibrillation were 
excluded from analysis and similarly in Paper II all patients that 
reported a history of heart failure at baseline were omitted from 
statistical analysis. 
For Paper III we used the control group from the SOS intervention 
study after excluding all patients with heart failure at baseline. 
Paper Ⅳ?
For this manuscript, we retrieved data from the SCAAR register and 
included all consecutive patients who had undergone PCI for ST-
elevation myocardial infarction (STEMI) in Sweden between 1st January 
2011 and 3rd May 2018.  The SCAAR registry data was merged with the 
COD registry to obtain the primary endpoint, mortality at 30 days and 
after 1 year. 
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STATISTICS 
PaperⅠ?
The data is presented as mean values with standard deviations or as 
percentages. For continuous variables, t-tests and a logistic-regression 
model for dichotomous variables was used for comparison between 
treatment groups. Using Kaplan Meier estimates, survival curves were 
generated and log rank test performed for comparison between groups. 
Relative-risk estimates expressed as hazard ratios were obtained by 
univariable and multivariable Cox proportional hazards regression 
models intention-to-treat principle was applied for all calculations. 
Patients who reported atrial fibrillation at baseline were excluded from 
all analyses (n=26).  
Paper Ⅱ 
The differences in changes in BMI between the surgery and control 
groups were analyzed with multilevel mixed-effects regression models. 
A competing-risks regression model was used to estimate the 
cumulative incidence of heart failure. Relative risk estimates expressed 
as sub-hazard ratios were obtained using univariable and multivariable 
models. Cox proportional hazard regression models were used to 
determine the treatment effect in subgroups where continuous variables 
were dichotomized by a median split, and the homogeneity of between-
group differences was evaluated. Patients who reported having a history 
of heart failure at baseline were excluded from all analyses (n=14).  
Paper Ⅲ 
Competing risks regression models were used to estimate the cumulative 
incidence of heart failure. Differences in sex and various categories of 
age and BMI were assessed with a log-rank test. Relative risk estimates 
expressed as sub-hazard ratios for preselected baseline risk factors were 
obtained using univariate and multivariable models. Analyses were also 
performed using time-dependent variables (atrial fibrillation and 
myocardial infarction) as predictors for incident heart failure. 
Competing risks regression models were used to estimate the cumulative 
incidence of heart failure. Differences in sex and various categories of 
age and BMI were assessed with a log-rank test. Relative risk estimates 
expressed as sub-hazard ratios for preselected baseline risk factors were 
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obtained using univariate and multivariable models.  Analyses were also 
performed using time-dependent variables (atrial fibrillation and 
myocardial infarction) as predictors for incident heart failure. Patients 
who reported having a history of heart failure at baseline were excluded 
from all analyses (n=10).  
Paper Ⅳ?
The participants were divided into four BMI categories according to the 
World Health Origination (WHO) classification (17): Underweight 
(BMI <18.5 kg/m2), normal weight (BMI 18.5-24.99 kg/m2), 
overweight (BMI 25-29.99 kg/m2) and obese (BMI > 30 kg/m2). 
Comparisons between groups at baseline were performed with analysis 
of variance (ANOVA) for normally distributed numeric data, Kruskal-
Wallis rank sum test for non-normally distributed data and Chi-square 
test for categorical data. Death is presented as a cumulative incidence 
function and the log rank test was used for comparison between groups. 
Univariable and multivariable-adjusted hazard ratios (HR) were 
calculated to evaluate the association between BMI categories and 
mortality using Cox proportional-hazards regression models. Patients 
with a BMI of 18.5–24.99 kg/m2 compatible with normal weight 
according to the WHO were used as the reference group. Penalized 
spline regression was applied to study the relationship between BMI as 
a continuous variable and all-cause mortality. The likelihood ratio test 
was used to examine the consistency of the association between 
subgroups.  
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RESULTS 
Baseline data for the SOS study are shown in Table 4. Although the 2 
study groups were fairly well balanced with respect to baseline 
characteristics, BMI was higher and several cardiovascular risk factors 
were less favorable in the surgery group (127). The differences are 
mainly explained by disparate weight changes occurring in the two 
groups during a delay between matching and baseline measurements: 
during the waiting time for bariatric surgery (on average more than 1 
year), participants awaiting surgery tended to gain weight and control 
subjects tended to lose weight. Thus, most differences between the study 
groups that were observed at matching and at baseline constitute 
disadvantages for the surgery group with respect to cardiovascular 
outcomes. 
Adverse events in the SOS study have been described in a previous 
paper (164). Bariatric procedures were performed with open surgery in 
89% of cases. There were 5 individuals (0.2%) in the surgery group and 
2 (0.1%) in the control group who died within 90 days of 
surgery/inclusion. In the surgery group, 151 (13.0%) of the participants 
had 193 postoperative complications. Of these, 46 persons (2.8%) 
needed additional surgery. 
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Table 4. Baseline variables of the two study groups. *  
  
Variable  
Surgery group  
(N=2010)  
Control group  
(N=2040)  
  
P-Value  
Male sex  590 (29)  590 (29)    
Female sex  1420 (71)  1447 (71)  0.79  
Age  47.2 ± 5.9  48.7 ± 6.3  <0.001  
Weight (kg)  121.0 ± 16.6  114.7 ± 16.5  <0.001  
Height (m)  1.69 ± 0.09  1.69 ± 0.09  0.68  
Body-mass index†  42.4 ± 4.5  40.1 ± 4.7  <0.001  
Anthropometry        
Waist-to-hip ratio†  0.99 ± 0.08  0.98 ± 0.07  <0.001  
Waist circumference  125.8 ± 11.0  120.2 ± 11.3   <0.001  
Hip circumference  127.1 ± 10.0  123.2 ± 10.0  <0.001  
Sagittal diameter  28.9 ± 3.7  27.4 ± 3.7  <0.001  
Neck circumference  43.7 ± 4.3  42.9 ± 4.29  <0.001  
Upper-arm circumference  39.8 ± 3.8  38.7 ± 3.8  <0.001  
Thigh circumference  75.5 ± 7.5  73.4 ± 7.5  <0.001  
Blood pressure        
Systolic  145.0 ± 18.8  137.9 ± 18.0  <0.001  
Diastolic  89.9 ± 11.1  85.2 ± 10.7  <0.001  
Pulse pressure†  55.2 ± 14.5  52.8 ± 13.0  <0.001  
Laboratory values        
Glucose (mmol/liter)  5.45 ± 2.11  5.20 ± 1.92  <0.001  
Insulin (mU/liter)  21.5 ± 13.7  18.0 ± 11.4  <0.001  
Triglycerides (mmol/liter)  2.25 ± 1.54  2.02 ± 1.41  <0.001  
Cholesterol (mmol/liter)        
HDL-cholesterol (mmol/liter)  1.20 ± 0.28  1.19 ± 0.29  0.84  
Uric acid (μmol/liter)  359.2 ± 79.8  352.3 ± 79.9  0.006  
ASAT (μkat/liter)  0.43 ± 0.23  0.39 ± 0.21  <0.001  
ALAT (μkat/liter)  3.12 ± 0.84  3.01 ± 0.87  <0.001  
ALP (μkat/liter)  3.12±0.84  3.01±0.87  <0.001  
Bilirubin (μmol/liter)  9.51 ± 4.28  9.93 ± 5.27  0.005  
Co-morbidities        
Daily smoking  518 (25.8)  424 (20.8)  <0.001  
Diabetes  215 (10.7)  232 (11.4)  0.520  
Sleep apnea  505 (25.1)  452 (22.2)  0.03  
Lipid-lowering therapy  36 (1.8)  33 (1.6)  0.67  
Previous myocardial infarction  31 (1.5)  29 (1.4)  0.76  
Previous cancer  46 (2.3)  49 (2.4)  0.81  
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Values are given as means ± standard deviation or numbers (percentages) as 
appropriate. ASAT = Aspartate aminotransferase; ALAT=Alanine 
aminotransferase; ALP=Alkaline phosphatase.  
*In Paper I patients with a history of atrial fibrillation were excluded from 
analysis (n=26) and for Papers II and III patients with a history of heart failure at 
baseline were excluded from analysis (n=14 and n=10, respectively).   
  
Figure 10. shows changes in BMI in patients for up to 20 years of 
follow-up. Bariatric surgery lowered the mean baseline BMI of 42.4 
kg/m2 by 25% at Year 1, by 18% at Year 6, by 16% at Year 15, and by 
16% at Year 20. The mean baseline BMI of 40.1 kg/m2 in the control 
group remained largely unchanged during follow-up. The average of all 
between-group differences in BMI during a 20-year follow-up was –8.0 
kg/m2 (95% CI -7.7 to -8.3); P< 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Change in body mass index during 15 years of follow-up. 
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Sleep apnea  505 (25.1)  452 (22.2)  0.03  
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Previous cancer  46 (2.3)  49 (2.4)  0.81  
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Values are given as means ± standard deviation or numbers (percentages) as 
appropriate. ASAT = Aspartate aminotransferase; ALAT=Alanine 
aminotransferase; ALP=Alkaline phosphatase.  
*In Paper I patients with a history of atrial fibrillation were excluded from 
analysis (n=26) and for Papers II and III patients with a history of heart failure at 
baseline were excluded from analysis (n=14 and n=10, respectively).   
  
Figure 10. shows changes in BMI in patients for up to 20 years of 
follow-up. Bariatric surgery lowered the mean baseline BMI of 42.4 
kg/m2 by 25% at Year 1, by 18% at Year 6, by 16% at Year 15, and by 
16% at Year 20. The mean baseline BMI of 40.1 kg/m2 in the control 
group remained largely unchanged during follow-up. The average of all 
between-group differences in BMI during a 20-year follow-up was –8.0 
kg/m2 (95% CI -7.7 to -8.3); P< 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Change in body mass index during 15 years of follow-up. 
 
 
 
 42 
 
PaperⅠ 
The participants had a median follow-up time of 19 years. First-time 
atrial fibrillation occurred in 247 (12.4%) of those in the surgical group 
and in 340 (16.8%) in the control group. There was a 31 % lower risk of 
developing atrial fibrillation in the surgery group as compared to the 
control group (HR 0.69; 95 % CI 0.59 to 0.82; P<0.001) (Figure 11). 
There was a 5-6-year delay before the incidence curves between the two 
groups separated. Younger individuals (P-value for interaction 0.002) 
and those with a high diastolic blood pressure (P-value for interaction 
0.024) had a better effect of surgical intervention compared to those who 
were older or with a low diastolic blood pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Surgical obesity treatment and the risk of atrial fibrillation during long-
term follow-up. 
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Paper Ⅱ 
First-time heart failure occurred in 188 (9.4%) of the participants in the 
intervention group and in 266 (13.1%) of those receiving usual care. The 
median follow-up was 22 years. The risk of developing heart failure in 
the surgery group was 35% lower than in the control group (sHR 0.65; 
95% CI 0.54–0.79; P< 0.001) (Figure 12). Data was pooled from the 
two study groups, the quartile of participants with the largest weight loss 
after 1 year (mean -41 kg) showed the greatest risk reduction (sHR 0.51; 
95% CI 0.30–0.70; P< 0.001). After adjustment for surgical intervention 
and potential baseline confounders, this association remained 
statistically significant (sHR 0.60; 95% CI 0.36–0.97; P=0.038).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Surgical obesity treatment and the risk of heart failure during long-term 
follow-up. 
 
 42 
 
PaperⅠ 
The participants had a median follow-up time of 19 years. First-time 
atrial fibrillation occurred in 247 (12.4%) of those in the surgical group 
and in 340 (16.8%) in the control group. There was a 31 % lower risk of 
developing atrial fibrillation in the surgery group as compared to the 
control group (HR 0.69; 95 % CI 0.59 to 0.82; P<0.001) (Figure 11). 
There was a 5-6-year delay before the incidence curves between the two 
groups separated. Younger individuals (P-value for interaction 0.002) 
and those with a high diastolic blood pressure (P-value for interaction 
0.024) had a better effect of surgical intervention compared to those who 
were older or with a low diastolic blood pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Surgical obesity treatment and the risk of atrial fibrillation during long-
term follow-up. 
 
 
 
43 
 
Paper Ⅱ 
First-time heart failure occurred in 188 (9.4%) of the participants in the 
intervention group and in 266 (13.1%) of those receiving usual care. The 
median follow-up was 22 years. The risk of developing heart failure in 
the surgery group was 35% lower than in the control group (sHR 0.65; 
95% CI 0.54–0.79; P< 0.001) (Figure 12). Data was pooled from the 
two study groups, the quartile of participants with the largest weight loss 
after 1 year (mean -41 kg) showed the greatest risk reduction (sHR 0.51; 
95% CI 0.30–0.70; P< 0.001). After adjustment for surgical intervention 
and potential baseline confounders, this association remained 
statistically significant (sHR 0.60; 95% CI 0.36–0.97; P=0.038).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Surgical obesity treatment and the risk of heart failure during long-term 
follow-up. 
 
 44 
 
Paper Ⅲ 
During a median follow-up of 20.1 years, the BMI of 40.1 kg/m2 
remained unchanged. First-time heart failure occurred in 266 of patients 
(13%) and was related to male sex, increasing age, hypertension, higher 
cholesterol, diabetes mellitus and elevated free thyroxine. eGFR was 
negatively related to heart failure risk. In unadjusted analysis, time-
dependent variables, atrial fibrillation (sHR ratio 5.38; 95% CI: 4.06-
7.14) and myocardial infarction sHR 5.54; 95% CI: 4.04-7.60) were 
statistically significant and strongly related to incident heart failure 
(Table 5).  
Table 5. Univariate and multivariate regression models as risk-factors for incident 
heart failure† including atrial fibrillation and myocardial infarction as time-
dependent variables. #  
 
Variable Model 1 Univariate 
Model 2 
Univariate 
Model 3 
AF and MI 
Model 4 
Multivariate 
Atrial Fibrillation 
(time‐dependent) 5.38 (4.06-7.14) ***  4.71 (3.47-6.39) *** 3.66 (2.65-5.04) *** 
Myocardial 
Infarction 
(time‐dependent) 
 5.54 (4.04-7.60) *** 4.59 (3.23-6.53) *** 3.71 (2.57-5.35) *** 
Sex 
(male vs female)    1.56 (1.12-2.18) ** 
Age (per 5 years)    1.35 (1.78-1.55) *** 
BMI 
(per 5 kg/m2)    1.05 (0.91-1.22) 
Hypertension (yes 
vs no)    1.16 (0.94-1.19) 
Cholesterol 
(per mmol/L    1.05 (0.70-1.47) 
Diabetes 
(yes vs no)    1.01 (0.67-1.47) 
Free thyroxine 
(per 5 pm/L)    1.28 (1.09-1.51) ** 
Smoking 
(yes vs no)    1.19 (0.86-1.65) 
Alcohol intake 
(per 10 g daily)    1.01 (0.87-1.18) 
eGFR (per 
10ml/min/1,73m2)    0.93 (0.80-1.08) 
 
†Values are given as sub-hazard ratios along with 95 % confidence intervals.  
AF=Atrial fibrillation and MI=Myocardial infarction are applied as time-
dependent covariates in all models  
** p <0.01; ***p <0.001  
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The relationships remained stable in adjusted analysis. In a subgroup of 
patients with available echocardiography (n=47), 53% of patients had 
heart failure with preserved ejection fraction (EF ≥45%) and 47 % had 
heart failure with reduced ejection fraction (EF <45%). 
Paper Ⅳ?
 A total of 25,384 subjects underwent coronary artery intervention for 
STEMI, and 5,529 (21.8%) deaths occurred within one year. Using 
normal weight as the reference value showed that obese people had the 
lowest 1-year mortality risk in unadjusted analysis HR 0.59 (95% CI; 
0.53–0.67), but when adjusted for age and sex the difference became 
non-significant, HR 1.06 (95% CI: 0.94-1.20). A low mortality risk was 
observed in patients with overweight in both unadjusted and age 
adjusted analysis, HR 0.63 (95% CI 0.57-0.69) and HR 0.86 (95% CI 
0.78-0.95), respectively (Figure 13). Underweight patients had the 
highest mortality in both unadjusted HR 2.22 (95% CI 1.69–2.92) and 
age adjusted analysis 1.72 (95% CI: 1.31-2.26). 
 
 
 
 
 
 
 
 
 
Figure 13. Age and sex adjusted penalised spline regression (95% CI, shaded area) 
with continuous risk relationship between BMI and all-cause mortality in patients with 
STEMI who underwent PCI. HR was referenced to the median value of 26.5. P<0,001 
for non-linearity. 
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DISCUSSION 
Obesity, weight loss and atrial fibrillation 
We observed that bariatric surgery induced a sustained weight loss in 
people with severe obesity, which resulted in a 31 % risk reduction for 
new-onset AF, as compared to the obese control group. It took several 
years before this benefit was observed, which was more pronounced in 
younger patients and in those with higher blood pressure. 
Obesity is an independent and modifiable risk factor for AF (165). The 
underlying mechanisms are probably multifactorial, but one important  
mediator is left atrial dilatation (79). Obesity directly contributes to the 
AF substrate through diastolic dysfunction, activation of pro-fibrotic 
pathways and atrial fibrosis (166). Obesity is associated with increased 
epicardial adipose tissue (EAT). The epicardial fat cells infiltrate the left 
atrium and induce fibrosis in the atrium (166). Atrial fibrosis causes 
conduction abnormalities manifested by intra-atrial conduction delay, 
reduced atrial voltage, presence of complex atrial electrograms, and 
electrical silence. These substrate changes contribute to the development 
and maintenance of AF (167).  
Lifestyle changes that target weight loss, physical activity, increased 
physical fitness and modification of risk factors like high blood pressure, 
diabetes, smoking and prior cardiac disease have also resulted in 
significant reductions in the AF burden and its recurrence (168-173).  
AF is prevalent in patients with OSA (174). Mechanisms by which OSA 
may increase the risk of AF include intermittent nocturnal hypoxemia 
and hypercapnia, and enhanced sympathetic tone with surges in blood 
pressure during apnoeic episodes leading to left atrial stretch through 
pressure and volume overload. A further mechanism is increased 
oxidative stress and inflammatory processes which contribute to left 
atrial remodelling and fibrosis resulting in aberrations in atrial structure 
and electrical activity (175-177). Obesity is concomitant risk factor for 
both, OSA (178) and AF. It has also been shown that OSA is associated 
with a hypercoagulative state which increases risk of stroke in AF 
patients (179). Treatment of AF is more effective when combined with 
CPAP therapy of OSA (180). Weight loss leads to improvement in OSA, 
thus providing health benefits (181). 
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Obesity, weight loss and heart failure 
In the present study with a median follow-up of 22 years, the surgery 
group displayed a 35% lower incidence of first-time HF diagnosis 
compared to the control group (sHR 0.65; 95% CI 0.54–0.79; P< 0.001). 
Separation of the cumulative incidence curves occurred after 5 years of 
intervention, showing that a sustainable weight loss over a long period 
of time is required to observe a primary preventive effect. A greater 
weight loss was associated with a larger risk reduction.  
Obesity leads to an increased cardiac output and hypertension, thus 
exerting increased preload and afterload on the left ventricle which in 
turn leads to the development of left ventricular hypertrophy (182). 
Also, obesity-associated diabetes, obstructive sleep apnea, and systemic 
inflammation (183), may cause excessive deposition of collagens, 
abnormal glycosylation of proteins and crosslinking of collagen in the 
myocardium (184, 185). This process leads to reduced diastolic 
compliance with increased left ventricular filling pressures and left atrial 
enlargement (186). The main result is an increased risk for the 
development of HFpEF and atrial fibrillation. On the other hand, 
obesity, and abdominal obesity in particular, is associated with 
atherosclerotic risk factors including hypertension, diabetes, and 
dyslipidemia which leads to atherosclerotic coronary 
plaque progression, coronary artery disease, and myocardial infarction  
(186, 187). Myocardial damage is followed by left ventricular 
remodeling in the form of left ventricular dilatation and a declining 
ejection fraction compatible with HFrEF. Heart failure with preserved 
ejection fraction represents more than half of all new HF diagnoses. 
More than 80% of patients with HFpEF are either overweight or obese 
(85, 188).   
Data from the Scandinavian Obesity Surgery Registry was compared 
with a Swedish nationwide registry of subjects treated with a structured 
intensive lifestyle program (189). This study found that gastric bypass 
surgery resulted in a greater weight loss than that attained by lifestyle 
intervention. Further, the surgery group had a significantly lower risk of 
HF compared to the lifestyle group. However, the incidence rates were 
low in both treatment groups, for surgery 0.41% and for the lifestyle 
intervention 0.76%, during a median follow-up of approximately 4 
years.  
 
49 
 
Obesity, HFpEF, AF and thromboembolic risk AF is a powerful predictor of the development of HFpEF and AF precedes the diagnosis by a few years(190, 191). A critical component of HFpEF is the development of atrial myopathy, which not only contributes to elevated pulmonary venous pressures and exertional dyspnea but also to atrial thrombus formation and thromboembolic stroke, independent of the presence of AF (192, 193). In clinical practice, the association between AF increased risk 
of stroke is widely accepted based on studies like that of Wolf et al, (194). It has been postulated that the mechanism behind the enhanced risk of stroke is directly related to AF causing chaotic atrial contraction which in turn drives thrombus formation. However, it has been shown that the decrease in flow velocity in the left atrium (LA), due to atrial myopathy and inflammation, predisposes to thrombus formation. (195). Obesity promotes systemic inflammation which adversely influences the biology of epicardial adipose tissue (EAT). Proinflammatory secretory adipokines are then produced that promote structural and functional changes in the underlying myocardium (196). When abnormal EAT is associated with the left ventricle (LV), the result is microcirculatory dysfunction and fibrosis. This leads to functional impairment of distensibility, increased cardiac filling pressure which all contribute to exertional dyspnea and development of HFpEF (69, 197).  Adverse effects, of proinflammatory EAT on the LA may also result in electroanatomic remodeling leading to atrial myopathy (198). These circumstances predispose the patient to blood stasis, spontaneous thrombus formation and stroke (192). The development of LA myopathy is central to the pathogenesis of both AF and HFpEF. In HFpEF, the greater LA stiffness is due to atrial fibrosis and this has been shown to be a strong determinant of AF which is a biomarker of atrial myopathy (199, 200).  Patients at risk for stroke or with a history of stroke monitored using continuous electrocardiography able to detect AF have not shown a temporal relationship between stroke and AF (201, 202). One-third of patients with stroke, presented AF only after the cerebrovascular event (203). To the contrary, HFpEF increases the risk of a subclinical cerebral infarction in patients without a history 
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of AF (204). Specifically, the severity of LA disease and the degree of LA fibrosis is associated with stroke and vascular brain injury in patients with or without AF (205, 206). Treatment according to the rhythm control strategy to reduce the burden of AF, using antiarrhythmic agents or catheter ablation where sinus rhythm was achieved, did not reduce the risk of stroke (207-209).  These observations are of importance with respect to our finding concerning atrial fibrillation and HFpEF. They support the importance of atrial myopathy as a component of HFpEF and as the primary source of the systemic thromboembolism in patients with obesity, rather than AF. In obese patients with HFpEF, the association between AF and stroke may be explained by AF being a biomarker of LA myopathy and not a direct mediator of thromboembolic events. 
Mechanisms linking obesity to heart failure. 
Obesity is an independent risk factor for developing heart failure (82). 
HF prevalence and incidence have increased due to the therapeutic 
advances in recent decades which have reduced mortality in HF. 
However, these advances are mainly limited to HFrEF. In the case of  
HFpEF, representing around 50% of all HF cases (210), there still 
remains a lack of specific therapeutic strategies other than treating co-
morbidities and obtaining fluid balance (211). 
Patients with HFpEF are more often obese than those with HFrEF. One 
study found that 41% of patients with HFpEF were obese (210). A 
systematic review from 2017 studying risk prediction models for 
incident HF showed that most studies were performed in a general 
population (212). Some investigations were performed in specific 
populations such as patients with diabetes, atrial fibrillation, coronary 
heart disease, hypertension, or valve disease. The predictors of HF 
included age, male sex, systolic blood pressure, diabetes, smoking, left 
ventricular hypertrophy, coronary heart disease, and myocardial 
infarction. 
To our knowledge no study has been performed to determine predictors 
of HF in an obese population. A study of this kind is of utmost 
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importance given the increasing prevalence of obesity and its 
association with HF. An early intervention by treating risk factors would 
allow for a preventive strategy in a risk population and, thereby, 
delaying or preventing HF onset.  
In our study of patients with BMI of 40.1 kg/m2, the risk factors for HF 
were similar to those observed in the general population and included 
advanced age male sex, hypertension, higher cholesterol levels, 
diabetes, and smoking. On the contrary normal renal function had a 
protective effect. 
Furthermore, we observed that free thyroxine levels were independently 
associated with risk for atrial fibrillation and heart failure, suggesting 
that subclinical forms of hyperthyroidism maybe of importance with 
respect to the development of cardiovascular disease in obesity. This 
relationship which has received little attention previously (213) was 
apparent in the total study group, especially among females. In a 
Norwegian study, a positive association between thyroid stimulating 
hormone (TSH) and BMI was observed (214). Leptin, secreted by 
adipose cells, plays a role in thyroid hormone regulation by promoting 
release of thyrotropin releasing hormone which stimulates TSH release 
(215). Leptin may also increase conversion of thyroxine (T4) to 
triiodothyronine (T3) (216). In the present series of investigations, the 
use of thyroid preparations was similar in both patients who developed 
AF and heart failure and in those who did not develop these conditions.  
Therefore, this is unlikely to explain our findings. The relationship 
between elevated thyroid levels within the normal range and incident 
heart failure in individuals with obesity deserves further research. 
 
Important predictors of cardiac dysfunction may vary over time. In the 
present study, atrial fibrillation and myocardial infarction as time 
varying variables displayed a strong correlation with incident heart 
failure in both unadjusted and adjusted analysis. Based on these 
findings we speculate that obesity causes heart failure through two 
separate mechanisms. The first mechanism appears to be related to 
increased preload and afterload leading to left ventricular hypertrophy 
atrial enlargement and atrial fibrillation. Further, diabetes (35), 
obstructive sleep apnea (36), and systemic inflammation (37) are likely 
to cause excessive deposition of collagens, abnormal glycosylation of 
proteins and crosslinking of collagen in the myocardium. This would 
lead to diastolic dysfunction and HFpEF. The second mechanism may 
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HFpEF, representing around 50% of all HF cases (210), there still 
remains a lack of specific therapeutic strategies other than treating co-
morbidities and obtaining fluid balance (211). 
Patients with HFpEF are more often obese than those with HFrEF. One 
study found that 41% of patients with HFpEF were obese (210). A 
systematic review from 2017 studying risk prediction models for 
incident HF showed that most studies were performed in a general 
population (212). Some investigations were performed in specific 
populations such as patients with diabetes, atrial fibrillation, coronary 
heart disease, hypertension, or valve disease. The predictors of HF 
included age, male sex, systolic blood pressure, diabetes, smoking, left 
ventricular hypertrophy, coronary heart disease, and myocardial 
infarction. 
To our knowledge no study has been performed to determine predictors 
of HF in an obese population. A study of this kind is of utmost 
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importance given the increasing prevalence of obesity and its 
association with HF. An early intervention by treating risk factors would 
allow for a preventive strategy in a risk population and, thereby, 
delaying or preventing HF onset.  
In our study of patients with BMI of 40.1 kg/m2, the risk factors for HF 
were similar to those observed in the general population and included 
advanced age male sex, hypertension, higher cholesterol levels, 
diabetes, and smoking. On the contrary normal renal function had a 
protective effect. 
Furthermore, we observed that free thyroxine levels were independently 
associated with risk for atrial fibrillation and heart failure, suggesting 
that subclinical forms of hyperthyroidism maybe of importance with 
respect to the development of cardiovascular disease in obesity. This 
relationship which has received little attention previously (213) was 
apparent in the total study group, especially among females. In a 
Norwegian study, a positive association between thyroid stimulating 
hormone (TSH) and BMI was observed (214). Leptin, secreted by 
adipose cells, plays a role in thyroid hormone regulation by promoting 
release of thyrotropin releasing hormone which stimulates TSH release 
(215). Leptin may also increase conversion of thyroxine (T4) to 
triiodothyronine (T3) (216). In the present series of investigations, the 
use of thyroid preparations was similar in both patients who developed 
AF and heart failure and in those who did not develop these conditions.  
Therefore, this is unlikely to explain our findings. The relationship 
between elevated thyroid levels within the normal range and incident 
heart failure in individuals with obesity deserves further research. 
 
Important predictors of cardiac dysfunction may vary over time. In the 
present study, atrial fibrillation and myocardial infarction as time 
varying variables displayed a strong correlation with incident heart 
failure in both unadjusted and adjusted analysis. Based on these 
findings we speculate that obesity causes heart failure through two 
separate mechanisms. The first mechanism appears to be related to 
increased preload and afterload leading to left ventricular hypertrophy 
atrial enlargement and atrial fibrillation. Further, diabetes (35), 
obstructive sleep apnea (36), and systemic inflammation (37) are likely 
to cause excessive deposition of collagens, abnormal glycosylation of 
proteins and crosslinking of collagen in the myocardium. This would 
lead to diastolic dysfunction and HFpEF. The second mechanism may 
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be related to the development of atherosclerotic risk factors including 
hypertension, diabetes, dyslipidemia and obesity itself leading to 
atherosclerotic coronary plaque progression, coronary artery disease, 
and myocardial infarction (43-45). Myocardial damage is followed by 
left ventricular remodeling in the form of left ventricular dilatation 
and declining ejection fraction (HFrEF). Diastolic heart failure is the 
most common heart failure phenotype in people with obesity (85, 217). 
Obesity paradox or ‘BMI paradox’?
In our study on the prognostic implications of BMI after STEMI, no 
prognostic significance of obesity was observed after adjustment for 
baseline covariates when compared with subjects of normal weight. 
After STEMI, patients who were overweight had the lowest mortality, 
and those who were underweight had the highest mortality. Similar 
results were seen in a study by Flegal et al who found obese patients 
(BMI > 30 kg/m2) with CAD had an increased mortality compared to 
those patients who were overweight (218).  
Several studies have shown a phenomenon known as the obesity 
paradox, where obesity confers a protective effect with regards to 
adverse outcomes after acute myocardial infarction and percutaneous 
coronary intervention (219, 220). In acute coronary syndromes, the 
relationship between BMI and mortality has been found to be U-shaped 
with the lowest mortality risk in patients with BMI around 35 kg/m2. 
Patients who are underweight or normal weight carry the highest risk 
(219, 220). The question arises whether it is the fat mass that exerts a 
protective effect. BMI is widely used in epidemiological studies as a 
surrogate for fat mass. However, BMI reflects the total body weight 
which includes both fat mass and lean mass. A lean body mass that is 
proportionally higher than the fat mass is associated with better 
prognosis (141).  Secondly, another factor that confers an improved 
prognosis is physical fitness. Increased physical activity and higher 
cardiorespiratory fitness are significant predictors of better CVD 
outcomes (152). Lavie et al, have shown that HF patients with a high 
CRF did not conform to the obesity paradox (153). Another factor of 
importance while studying the obesity paradox is to account for the 
unintentional weight loss. Cachexia due to cancer and other chronic 
diseases generate a low BMI that is associated with poor prognosis (142, 
221). To study the obesity paradox an optimal design should account for 
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confounding factors like body composition, the CRF and whether 
weight loss is unintentional.  
The nomenclature obesity paradox has it flaws as it reflects as fat mass 
having a protective effect whereas it has been shown that there are other 
confounders that improve the survival once you have established CVD. 
Designating it as ‘BMI paradox’ is more applicable.  
On a closing note a quote by Carl Lavie is quite appropriated: ‘Better 
Fat and Fit Than Lean and Lazy’.  
Study strengths and limitations 
The SOS study was not randomized as Swedish ethical review boards 
did not approve this design, because of a high postoperative mortality in 
the 1980s. The surgery group was, therefore, comprised of individuals 
who expressed a preference for treatment with bariatric surgery. It 
should also be considered that a significant number of subjects in the 
obese control group underwent bariatric surgery during follow-up. Thus, 
many analyses were performed as per protocol and not as intention to 
treat. Only 13% of participants in the surgery group received GBP, a 
method that offers the greatest weight loss and is the surgical technique 
that is most frequently applied in Sweden today. A majority in the 
surgical group received treatment with surgical techniques including 
VBG and GB that have largely been abandoned today. The choice of 
surgical method was based on the techniques that were commonly 
applied when the study was initiated in 1987. Atrial fibrillation and heart 
failure were not a pre-specified endpoint of the trial and these diagnoses 
were obtained by crosslinking the SOS database with the Swedish 
National Registers.  
The main strengths of the SOS study include a large study cohort, a 
prospective controlled design, and a long period of follow-up and 
excellent patient compliance with respect to study follow-up. 
The main limitation of the SCAAR registry study, is its observational 
nature, which impedes from making any causal inferences. As only 
surviving hospitalized patients are included, the possibility of selection 
bias, residual confounding and survival bias cannot be ruled out. BMI 
as a surrogate for obesity, has some limitation since it does not 
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distinguish between body fat and lean body mass nor does it provide 
information about fat distribution. Waist circumference as a measure of 
abdominal adiposity was not available. It was not possible to determine 
whether weight loss was intentional or unintentional. Lastly, cause-
specific mortality data was not studied.  
The strength of the study based on the SCAAR register includes a large 
sample size of real-world data and a homogenous group of patients 
treated with PCI for ST-elevation myocardial infarction. 
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CONCLUSIONS 
In people with severe obesity, bariatric surgery induces a substantial 
weight loss that is maintained over time. This resulted in significant 
primary preventive effect on the occurrence of atrial fibrillation and the 
development of heart failure. A greater weight loss resulted in a larger 
risk reduction for heart failure. Atrial fibrillation, which is reflected by 
diastolic dysfunction and myocardial infarction, which is related to 
systolic dysfunction, include two different mechanistic pathways for the 
development of heart failure. After adjustment for age and sex 
overweight displayed the lowest risk for 30-day and 1-year mortality 
after PCI treatment of STEMI and underweight the highest. 
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FUTURE PERSPECTIVES 
The medical profession should be more pro-active in assessment of fat-
mass in patients and to give appropriate advice about life style 
intervention like PA and CRF and dietary intake. Where appropriate 
bariatric surgery should be recommended. 
More studies are required to map out the obesity paradox using better 
quantification of obesity, distinguishing between intentional and 
unintentional weight loss, and assessing the CRF. 
Optimal treatment of baseline risk factors, together with treatment of 
atrial fibrillation and myocardial infarction may promote a further 
lowering of heart failure incidence and thereby, improving outcomes in 
patients with obesity.?
Obesity is associated with an increase in epicardial fat mass and its close 
anatomical location the heart makes it interesting candidate in the 
development heart diseases and, therefore, making it an enthralling area 
for future research.  
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